A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Obesity

Treatments: Drug: MK0557

Study type: Interventional

Funder types: Industry

Identifiers

NCT00533598

2007_613

0557-006

Details and patient eligibility

About

The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.

Sex: All

Ages: 21 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study

Exclusion criteria

• You are or plan to become pregnant
• You have smoked or used nicotine within 6 months of the study
• History of abusing alcohol and/or drugs
• History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
• Have participated in a weight loss program 3 months before the study or during the course of the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind